MAPT and Alzheimer disease: Recent studies have shown that cutting down Aβ production or enhancing Aβ clearance by gene editing can significantly improve cognitive function and cut down neuroinflammation in AD models, and also normalize tau protein phosphorylation levels, which in turn improves cognitive deficits and attenuates other AD-associated pathological alterations (Chacko et al., 2023; Tripathi et al., 2024).